Inquis Medical

Executive Summary

Inquis Medical is a privately held medical device company dedicated to transforming the treatment of venous thromboembolic (VTE) diseases, with a primary focus on pulmonary embolism (PE). Founded in 2018 and headquartered in Menlo Park, CA, the company has developed the AVENTUS Precision Thrombectomy System, an innovative platform that integrates efficient clot removal with autologous blood reinfusion, potentially reducing complications and improving patient outcomes. The system addresses a critical unmet need in the management of acute PE, where rapid and safe thrombectomy is essential. With a strong product design and a clear clinical value proposition, Inquis Medical is well-positioned to capture share in the growing interventional thrombectomy market, estimated at over $1 billion annually. As the company progresses toward commercialization, key milestones such as regulatory clearance and clinical validation will be critical drivers of value.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for AVENTUS Precision Thrombectomy System70% success
• Q3 2026Series B or C Funding Round to Support Commercial Launch80% success
• Q2 2026Presentation of Pivotal Clinical Trial Results at Major Interventional Cardiology Conference60% success